Adjuvant interferon alpha therapy in renal cell carcinoma (RCC): Prognostic value of DNA cytophotometry

Anticancer Research

Volumn 19, Issue 2 C, 1999, Pages 1493-1495

  Basting, Ralf ^a   Corvin, Stefan ^a   Händel, Dirk ^a   Hinke, Axel ^a   Schmidt, Dieter ^a  

^a Kreiskrankenhaus Alt /Neuötting ^*

Author keywords

Adjuvant therapy; Interferon alpha; Ploidy; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON;

ANEUPLOIDY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; CYTOPHOTOMETRY; DIPLOIDY; DNA DETERMINATION; DRUG EFFICACY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; NEPHRECTOMY; PATIENT SELECTION; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

ANEUPLOIDY; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; DIPLOIDY; DNA, NEOPLASM; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; NEOPLASM STAGING; NEPHRECTOMY; PLOIDIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0033025852     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Pizzocaro G, Piva L, Di Palo A, Grosso G, Colavita M: Adjuvant interferon (IFN) to radical nephrectomy in Robson's Stages II and III renal cell cancer (RCC), a multicenter study. J Urol 159: 150, 1998.
2. Al-Abadi H, Nagel R: Zellkern-DNS-Analyse bei Nierenkarzinomen unter Berücksichtigung des morphologischen Malignitätsgrades. Akt Urol 18: 137-141, 1987.
3. Thrasher JB, Paulson DF: Prognostic factors in renal cancer. Urol Clin North Am 20: 247-262, 1993.
4. Bartoletti R, Selli C, Nicolo G, Margallo E, Amorosi A: Cytofluorometric and cytogenetic evaluation of renal cell carcinoma: correlations with the clinical course. Urol Int 58: 1-7, 1997.
5. Selli C, Nicolo G, Margallo E, Bartoletti R, Amorosi A: Cytofluorometric evaluation of nuclear DNA content distribution in renal neoplasms treated by conservative surgery. Urol Int 57: 151-157, 1996.
6. Ljungberg B, Larsson P, Stenling R, Roos G: Flow cytometric deoxyribonucleic analysis in stage I renal cell carcinoma. J Urol 146: 697-699, 1991.
7. Koss LG, Werst RP, Simmons DA, Deitch D, Herz F, Fried SZ: Predictive value of DNA measurements in bladder washings, comparison of flow cytometry, and cytology in patients with a past history of urothelial tumors. Cancer 64: 916-924, 1989.
8. Atzpodien J, Hänninen EL, Kirchner H, Bodenstein H, Pfreundschuh M, Rebmann U, Metzner B, Illinger HJ, Jakse G, Niesel T, Scholz HJ, Wilhelm S, Pielmeier T, Zakrzewski G, Blum G, Beier J, Müller GW, Duensing S, Anton P, Allhoff E, Jonas U, Poliwoda H: Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal carcinoma. J Clin Oncol 13: 497-501, 1995.
9. Lümmen G, Goepel M, Möllhoff S, Hinke A, Otto T, Rübben H: Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma. J Urol 155: 455-458, 1996.
10. Kriegmair M, Hofstetter A: Interferon therapy in urology. Urologe [A] 28: 116-121, 1989.
11. Choudhury M, Efros M, Mittelmann A: Interferons and interleukins in metastatic renal cell carcinoma. Urology 41: 67-72, 1993.
12. Muss HB: Interferon therapy for renal cell carcinoma. Sem Oncol 14: 36-42, 1987.
13. Larsson P, Roos G, Stenling R, Wilson GD, Ljungberg B: Cell proliferation in renal cell carcinoma - a comparative study of cell kinetic methods. Urol Res 24: 291-295, 1996.